Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data

DNY59/iStock via Getty Images Investment Overview- Background To Stunning Rise Of GLP-1 Analogue Drug Class Doubtless, readers will be familiar with the Wegovy / Zepbound, Ozempic / Mounjaro, tirzepatide / semaglutide "miracle" weight loss story by now - but to recap: Semaglutide is a glucagon-like peptide-1 receptor agonist, or "GLP-1" agonist / analogue developed by Danish Pharma Novo Nordisk (NVO). These types of drugs have been used for many years to treat type 2 diabetes, as they prompt the body to ...